HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Navigating the Changing Landscape in HER2-Positive Breast Cancer

March 9th 2020

The paradigm for treating patients with HER2-positive breast cancer is changing throughout the spectrum of the disease as a result of recent clinical trial findings regarding novel and established treatment regimens, according to Sara A. Hurvitz, MD

Dr. Crew on the APHINITY Trial Results in HER2+ Breast Cancer

March 7th 2020

Katherine D. Crew, MD, MS, discusses the results of the APHINITY trial in HER2-positive breast cancer.

Dr. Robson on the Potential Utility of Tucatinib in HER2+ Breast Cancer

March 6th 2020

Mark E. Robson, MD, discusses the potential utility of tucatinib in the treatment of patients with HER2-positive breast cancer.

Dr. Chung on the Rationale of the KEYNOTE-811 Trial in HER2+ Gastric Cancer

March 6th 2020

Hyun C. Chung, MD, PhD, discusses the rationale of the KEYNOTE-811 study in HER2-positive gastric cancer.

Dr. Tolaney on Novel Approaches in Treating HER2-Positive Breast Cancer

March 4th 2020

Sara M. Tolaney, MD, MPH, discusses novel approaches in treating patients with HER2-positive breast cancer.

FDA Approves Neratinib Combo for HER2+ Breast Cancer

February 26th 2020

The FDA has approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received ≥2 prior anti–HER2-based regimens in the metastatic setting.

FDA Accepts BLA for Subcutaneous Fixed-Dose Pertuzumab/Trastuzumab in HER2+ Breast Cancer

February 25th 2020

The FDA has accepted a Biologics License Application for a fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, administered by subcutaneous injection in combination with intravenous chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer.

Retrospective Results Show High pCR With Dose-Dense Regimen in HER2+ Breast Cancer

February 15th 2020

Jasmeet C. Singh, MD, discusses the findings of a retrospective analysis and how they may impact treatment for patients with HER2-positive breast cancer.

Dr. Crew on Treatment in Favorable-Risk HER2+ Breast Cancer

February 14th 2020

Katherine Crew, MD, MS, discusses treatment for patients with favorable-risk early-stage HER2-positive breast cancer.

Dr. Hamilton on the Results of the KATHERINE Trial in HER2+ Breast Cancer

February 14th 2020

Erika P. Hamilton, MD, discusses the superiority of ado-trastuzumab emtansine (T-DM1; Kadcyla) in the phase III KATHERINE study.

FDA Grants Priority Review to Tucatinib in HER2+ Breast Cancer

February 13th 2020

The FDA has granted a priority review designation to a new drug application for tucatinib for use in combination with trastuzumab and capecitabine for the treatment of patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including patients with brain metastases, following at least 3 prior HER2-directed agents separately or in combination, in the neoadjuvant, adjuvant, or metastatic setting.

Dr. Lin on CNS-Specific Outcomes With Neratinib in HER2+ Breast Cancer

February 12th 2020

Nancy Lin, MD, discusses central nervous system–specific outcomes with neratinib (Nerlyx) in HER2-positive breast cancer.

SABCS Showcased Novel Agents in the HER2+ Breast Cancer Armamentarium

February 7th 2020

Katherine D. Crew, MD, discusses the results of HER2CLIMB and DESTINY-Breast01, as well as other impactful data in HER2-positive breast cancer that emerged from the 2019 San Antonio Breast Cancer Symposium.

Dr. Hamilton on the DESTINY-Breast01 Trial in HER2+ Breast Cancer

February 6th 2020

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the phase II DESTINY-Breast01 trial in advanced HER2-positive breast cancer.

Updated Data Refine Adjuvant Paradigm in HER2+ Early Breast Cancer

February 5th 2020

Katherine D. Crew, MD, discusses the updated results of the KATHERINE trial, as well as other data regarding the adjuvant treatment paradigm in early-stage HER2-positive breast cancer.

Dr. Crew on New Research in Advanced HER2+ Breast Cancer

February 4th 2020

Katherine Crew, MD, MS, discusses new research in the advanced HER2-positive breast cancer landscape.

Tucatinib Takes Step Toward EU Approval in HER2+ Breast Cancer

January 31st 2020

The European Medicines Agency has validated a Marketing Authorization Application for tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases, who have received ≥2 prior anti-HER2 treatment regimens.

Patients With HER2+ Breast Cancer Gain Potent Option in Third-Line Setting

January 31st 2020

Fam-trastuzumab deruxtecan- nxki received a green light from the FDA in December 2019 after updated data demonstrating a confirmed objective response rate of 60.9% were presented at the 2019 San Antonio Breast Cancer Symposium.

Adjuvant T-DM1 Approved in China for HER2+ Early Breast Cancer

January 24th 2020

China’s State Administration of Drug Administration has approved ado-trastuzumab emtansine for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual disease following a neoadjuvant trastuzumab-based regimen.

Dr. Hurvitz on the Evolution of Treatment in Metastatic HER2+ Breast Cancer

January 17th 2020

Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the evolution of treatment in metastatic HER2-positive breast cancer.